12 Feb 2026
The Respiratory and Sleep Clinical Network has submitted a proposal to PHARMAC to widen access to Trikafta and Kalydeco, and fund Alyftrek, for people with cystic fibrosis from 1 April 2026.
The submission strongly supports extending modulator therapy to younger children with eligible mutations, enabling treatment before lung damage develops. It also raises considerations around maintaining the link to the FDA's mutation eligibility list and aligning sweat chloride criteria across all three medications.
You can read the full submission below 👇